Floatz logo

Sargramostim

Leukemia

Virginia Commonwealth Universityprotein_peptidePhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
65/ 100

Competitive context

125 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
PEGASPARGASE
Dana-Farber Cancer Institute
Phase 3BB
FILGRASTIM
Hospital General de Mexico
Phase 4BB
Idarubicine
Affiliated Hospital of Nantong University
Phase 3BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB

View all 50 →

Same molecule, other indications

Sargramostim is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →